10-K
Annual Report
DAY ONE BIOPHARMACEUTICALS, INC.
DAWN
NASDAQ
CIK: 1845337
File #: 001-40431
Balance Sheet
36 line items · 2 periods
XBRL
| Item | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|
Current assets: | ||
Cash and cash equivalents | 230,784,000 | 85,262,000 |
Money Market Funds | 47,003,000 | 18,765,000 |
U.S. government agency securities | 63,202,000 | 24,800,000 |
Cash Equivalents | 220,850,000 | 43,565,000 |
US Treasury Securities | 110,645,000 | — |
Short-term investments | 135,563,000 | 257,007,000 |
Prepaid expenses and other current assets | 8,927,000 | 5,605,000 |
Total current assets | 375,274,000 | 347,874,000 |
Property and equipment, net | 208,000 | 20,000 |
Operating lease right-of-use asset | 352,000 | 699,000 |
Deposits and other long-term assets | 214,000 | 469,000 |
Total assets | 376,048,000 | 349,062,000 |
Liabilities and stockholders' equity | ||
Current liabilities: | ||
Accounts payable | 2,576,000 | 260,000 |
Accrued expenses and other current liabilities | 26,524,000 | 15,950,000 |
Current portion of operating lease liabilities | 408,000 | 405,000 |
Total current liabilities | 29,508,000 | 16,615,000 |
Long-term portion of lease liabilities | 0 | 408,000 |
Total liabilities | 29,508,000 | 17,023,000 |
Stockholders' equity | ||
Common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 87,227,132 and 73,458,176 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 9,000 | 7,000 |
Additional paid-in-capital | 805,107,000 | 601,771,000 |
Accumulated other comprehensive loss | 9,000 | (71,000) |
Accumulated deficit | (458,585,000) | (269,668,000) |
Total stockholders' equity | 346,540,000 | 332,039,000 |
Redeemable Noncontrolling | 0 | 0 |
Incentive Shares | 0 | 0 |
Common Shares | 0 | 0 |
Redeemable convertible preferred shares - Preferred Stock | 0 | 0 |
Accumulated Deficit | (458,585,000) | (269,668,000) |
Additional Paid-in Capital | 805,107,000 | 601,771,000 |
Common Stock | 9,000 | 7,000 |
Accumulated Other Comprehensive Loss | 9,000 | (71,000) |
Total liabilities and stockholders' equity | 376,048,000 | 349,062,000 |